ClinicalTrials.Veeva

Menu

Gabapentin Versus Transdermal Fentanyl Matrix for Chronic Neuropathic Pain

Seoul National University logo

Seoul National University

Status and phase

Completed
Phase 4

Conditions

Neuropathic Pain
Spinal Stenosis

Treatments

Drug: transdermal fentanyl matrix, gabapentin

Study type

Interventional

Funder types

Other

Identifiers

NCT01127100
Neuropathic pain 2010

Details and patient eligibility

About

Gabapentin is a first line medication and fentanyl is second line medication in neuropathic pain. But, there is no head to head study on the efficacy of those medication in neuropathic pain.

The hypothesis of this study is that the efficacy of the transdermal fentanyl matrix is not inferior to the gabapentin in neuropathic pain.

Enrollment

108 patients

Sex

All

Ages

20 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • patients are 20 years of age or older
  • patients had chronic pain for more than 3 months and average pain score for last 3 days is not less than 4 (NRS)
  • neuropathic pain caused by the spinal stenosis (radiating pain, motor or sensory change
  • positive MRI finding or radiculopathy was confirmed by the EMG/NCS or not less than 12 points in the S-LANSS score assessment
  • patients who can make out the questionnaire
  • patients have agreed with the informed consent

Exclusion criteria

  • patients who have experience with gabapentin, pregabalin, fentanyl matrix, long-acting strong opioid (CR oxycodone, SR morphine)
  • patients who have other causes of neuropathy such as hypothyroidism, Vit B12 deficiency, connective tissue disease, etc.
  • patients who have other disease which causes more pain compared with neuropathic pain
  • patients with a history of drug or alcohol abuse
  • patients who are pregnant or have the possibility of pregnancy
  • patients who are unable to use a transdermal system due to skin disease
  • patients with a serious mental disease
  • patients with a history of hypersensitivity to opioid analgesics
  • patients with a chronic pulmonary disease or respiratory depression
  • patients combined with industrial accidents or traffic accidents
  • at investigator's discretion, any condition where a subject cannot take part in the clinical study on the ground of warning, cautions, and prohibition in study investigator's brochure

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Single Blind

108 participants in 2 patient groups

Transdermal fentany matrix
Experimental group
Description:
Transdermal fentanyl matrix is second-line medication on the neuropathic pain but gabapentin is the first-line medication. So, transdermal fentanyl matrix is experimental arm and gabapentin is active comparator arm.
Treatment:
Drug: transdermal fentanyl matrix, gabapentin
gabapentin
Active Comparator group
Description:
Gabapentin is the first-line medication in neuropathic pain. So, gabapentin is active comparator in this study and transdermal fentanyl matrix is experimental.
Treatment:
Drug: transdermal fentanyl matrix, gabapentin

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems